Dopamine-Induced Nonmotor Symptoms of Parkinson's Disease by Park, Ariane & Stacy, Mark
SAGE-HindawiAccess to Research
Parkinson’s Disease
Volume 2011, Article ID 485063, 6 pages
doi:10.4061/2011/485063
Review Article
Dopamine-Induced Nonmotor Symptoms ofParkinson’sDisease
ArianePark1 andMark Stacy2
1Department of Neurology, The Ohio State University, Columbus, OH 43210, USA
2Division of Neurology, Duke University Medical Center, Durham, NC 27705, USA
Correspondence should be addressed to Mark Stacy, mark.stacy@duke.edu
Received 15 October 2010; Accepted 14 February 2011
Academic Editor: Irena Rektorova
Copyright © 2011 A. Park and M. Stacy. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Nonmotor symptoms of Parkinson’s disease (PD) may emerge secondary to the underlying pathogenesis of the disease, while
others are recognized side eﬀects of treatment. Inevitably, there is an overlap as the disease advances and patients require
higher dosages and more complex medical regimens. The non-motor symptoms that emerge secondary to dopaminergic
therapy encompass several domains, including neuropsychiatric, autonomic, and sleep. These are detailed in the paper.
Neuropsychiatric complications include hallucinations and psychosis. In addition, compulsive behaviors, such as pathological
gambling, hypersexuality, shopping, binge eating, and punding, have been shown to have a clear association with dopaminergic
medications. Dopamine dysregulation syndrome (DDS) is a compulsive behavior that is typically viewed through the lens of
addiction, with patients needing escalating dosages of dopamine replacement therapy. Treatment side eﬀects on the autonomic
system include nausea, orthostatic hypotension, and constipation. Sleep disturbances include fragmented sleep, nighttime sleep
problems, daytime sleepiness, and sleep attacks. Recognizing the non-motor symptoms that can arise speciﬁcally from dopamine
therapy is useful to help optimize treatment regimens for this complex disease.
1.Neuropsychiatric
Hallucinations and psychosis have long been known to be
associated with dopaminergic therapy. Psychosis in PD refers
to the combination of chronic hallucinations and delusions
occurring in the setting of otherwise clear senses. Hallucina-
tions can involve various sensory modalities; however, visual
hallucinations are the most common. Some may be benign
and nonbothersome, while others can be terribly frightening
topatients.Riskfactorsfordevelopinghallucinationsinclude
older age, longer duration of PD, history of sleep disorder,
depression, and coexisting cognitive impairment [1, 2].
Interestingly, there has been no evidence that increased
dose or speciﬁc dopaminergic drug class (agonists versus
L-dopa) is related to this problem [1, 3], and it is clear
that hallucinations and psychosis are not just mere side
eﬀects of treatment. The likely pathogenesis is multifactorial
involving pharmacologic mechanisms in conjunction with
disease-related elements. Treatment for chronic hallucina-
tions includes reduction of dopaminergic medications and
discontinuationofanticholinergicsorotherdrugs.Ifneeded,
antipsychotic medications may be used. Clozapine has
demonstrated eﬃcacy in a double-blind placebo-controlled
trial [4]; however, in clinical practice quetiapine is preferred,
despite the fact that, it has not been proven more eﬀective
than placebo in clinical trials [5–7].
Dopaminergic medications, particularly dopamine ago-
nists [8], are known to be associated with impulse control
disorders, with no diﬀerencesseen between speciﬁc drugs [9,
10] .T h ep r e v a l e n c eo fa n yI C Di nP Dp a t i e n t so nd o p a m i n e
agonists ranges from 13.7 to 17.1% [11]. The formal de-
ﬁnition for impulse control disorders in the Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV-TR)
is a group of psychiatric disorders characterized ﬁve stages
of symptomatic behavior. Essential to this is “a failure to
resist an impulse, drive or temptation to perform an act
that is harmful to the person or to others.” Patients feel
an increasing sense of tension or arousal before the act,
experience pleasure, gratiﬁcation, or relief while committing
the act, and ﬁnally feel a sense of relief from the urge
after the act. Individuals may or may not feel regret, self-
reproach, or guilt about these activities [12]. Pathological2 Parkinson’s Disease
gambling (PG) is the most extensively studied ICD in PD,
ﬁrst noted in 2003 by Driver-Dunckley et al. [13]i na
retrospective study of 1,884 patients. The essential feature of
pathological gambling is that it is a “persistent and recur-
rent maladaptive gambling behavior that disrupts personal,
family, or vocational pursuits” [12]. A recent prospective
study of 200 PD patients reported a prevalence of PG
to be as high as 7% [14]. Compulsive sexual behavior
or hypersexuality as well as compulsive buying are not
formally deﬁned in the DSM-IV-TR. However, they are
easily identiﬁed problems once patients cross the threshold
of reasonable urge into compulsions leading to personal,
familial, and/or occupational suﬀering and consequences.
Hypersexuality can include not only increased libido, but
also exhibitionism, excessive masturbation, phone/internet
sex, use of prostitutes, and new sexual orientations. More
seriously, criminal behaviors such as rape, pedophilia, and
incest have been reported [15]. Hypersexuality can be seen
in up to 4% of PD patients [16]. Compulsive buying of
items that are unnecessary and go unused (i.e., shirts, shoes,
jewelry) has been reported in up to 5.7% of PD patients [17]
and often leads to ﬁnancial distress. These patients tend to
havetraits of both obsessive-compulsive and impulse control
disorders [18]. Binge eating is a proposed diagnosis in the
DSM-IV-TR as an eating disorder marked by “uncontrolled
eating of food that is larger in amount than most people
would eat in a similar period of time under similar cir-
cumstances, without emesis or laxative abuse” [12]. Patients
have a sense of lack of control over eating during the
episode, and some report nocturnal awakening with an
extreme sweet craving, eating excessive amounts. This has
been reported in 4.3% of PD patients [17]. Punding refers
to stereotypic, complex, and repetitive behavior involving
meaningless activities (i.e., examining, sorting, collecting,
arranging, dismantling objects) sometimes to the point of
ignoring basic needs such as eating and sleeping. Patient may
be irritable when interrupted, and this behavior can lead to
social avoidance and isolation. Interestingly, participating in
these activities may or may not be enjoyable for patients.
One study involved demonstrated a punding prevalence of
1.4% in an ambulatory PD population [19], but it has been
reported to be as high as 14% [20].
Dopamine dysregulation syndrome (DDS), also known
as hedonistic homeostatic dysregulation (HHD), is a neuro-
psychiatric disorder characterized by addiction, self-medi-
cation, and escalation of antiparkinsonian medication. It is
thought to have a prevalence of approximately 3.4% [21].
Not all patients with DDS have an ICD, although the
majority of patients with DDS also exhibit punding [22].
Unlike ICD, DDS is typically associated with levodopa or
short-acting dopamine agonist medications (i.e., subcuta-
neous apomorphine) [23], although it has been described
with ergot- and nonergot-derived dopamine agonists as well
[24]. These patients often do not have insight into the
problem and will often take larger- than-recommended total
daily doses, far beyond what is necessary for their motor
disabilities. Unfortunately, they do not recognize the harm
it is causing to themselves and their loved ones and demand
increasing quantities of medication despite the development
of complications (i.e., dyskinesia, “oﬀ” state dysphoria). At-
tempts to reduce the dose are met with great resistance,
making management quite diﬃcult.
DDSbehaviors can be viewed as botha substance depen-
dence disorder and an addiction. In fact, the term hedonic
homeostaticdysregulationwascoinedbasedontheaddiction
model that addicts take drugs not only for pleasure but
also to avoid unpleasant withdrawal symptoms [25, 26].
Other theories of psychostimulant addiction including plea-
sure seeking, habit models, and chronic neuroadaptations
induced in the ventral striatum and nucleus accumbens may
help to explain DDS [24]. Supportive of addiction theories,
one study utilizing positron emission tomography (PET)
showed that PD patients with DDS had enhanced levodopa-
induced ventral striatal dopamine release, perhaps due to
sensitization, compared with levodopa-treated patients with
PD who did not have DDS [27]. In fact, it has beentheorized
that the pulsatile stimulation of striatal dopamine receptors
inherent in the oral delivery of dopamine may cause changes
in the basal ganglia circuitry leading to sensitization [28],
leading to motor ﬂuctuations, dyskinesia, and possibly even
DDS. Interestingly, patients without PD but treated with
dopaminergic therapy for restless legs syndrome have also
been reported to have DDS, indicating that drug exposure
itself plays a physiologic role, perhaps in triggering these
behaviors [13, 29].
Treatment for these impulse control disorders starts with
recognizing that they exist. It is important for physicians to
be aware of these neuropsychiatric side eﬀects of dopamin-
ergic therapy and to actively screen for them, as patients
often do not volunteer the information either because they
do not have insight into these issues, they are in denial, or
they are embarrassed. This is where family/caregiver input
can be particularly helpful. One study found that only 25%
of PD patients with an active ICD were identiﬁed clinically
[9]. The risk factor proﬁle of these patients includes male
gender, early-onset PD, novelty-seeking personality, history
of substance dependence, history of depression, high alcohol
intake, and early emergence of dyskinesia [30–32]. Once
identiﬁed, a thorough review of the patient’s mediations is
warranted, followed by a systematic reduction or cessation
of dopaminergic treatment. For ICDs, this would involve
dopamine agonists. If parkinsonism worsens, it may be
prudent to concomitantly increase levodopa. In DDS, the
strategy is reversed and levodopa is the initial agent to
wean, with a subsequent increase in dopamine agonist
treatment. However, as previously mentioned, patients with
DDS often are not complaint with this, and therefore coun-
seling with both the patients and their families/caregivers
is important. As far as additional pharmacologic options,
antidepressants for obsessive thoughts and antiandrogens
to help decrease hypersexuality may be considered. A
recent study found amantadine to be eﬀective in the
treatment of pathological gambling in PD [33]. Deep
brain stimulation to the subthalamic nucleus may allow
dopaminergic drug reduction and therefore improvement
in these symptoms [34, 35]a l t h o u g hD D Sa n dI C D sm a y
worsen or develop for the ﬁrst time after DBS surgery
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2.Autonomic
Nausea is very commonly associated with dopamineric
therapy. It is thought to result from stimulation of the area
postrema [37]. Orthostatic hypotension and constipation
may be intrinsic to neurodegenerative changes related to
PD, but these can clearly worsen with dopaminergic therapy.
Higher rates of constipation and nausea have been seen
in patients treated with dopamine agonists versus levodopa
[38],suggesting that the diﬀerentpharmacodynamic proper-
ties of the various dopamine formulation may contribute to
adverse eﬀects.Autonomicsymptoms in PDare attributedto
the involvement of the central and peripheral postganglionic
autonomic nervous system. Constipation in PD may be
attributed to Lewy body pathology in the myenteric plexus
and colonic sympathetic denervation. These symptoms are
exceedingly common. One study found that 60% of patients
had orthostatic hypotension early in the course of the disease
[39], and 58% of PD patients may experience constipation
[40].
In the vast majority of cases, nausea subsides with a slow
titration up on dosage, with the addition ofcarbidopaor do-
mperidone, a peripheral dopamine receptor blocking agent,
or taking dopaminergic medications with food.
Conservative measures for the treatment of orthostatic
hypotension include increasing salt and ﬂuid intake, elevat-
ing the head of the bed (>30 degree incline), and the use
of thigh and abdominal compression bands. Patients should
be advised to avoid Valsalva maneuvers, warm temperatures,
and meals rich in carbohydrates and alcohol, as these may be
triggers. Pharmacologic treatments include ﬂudrocortisone,
a salt-retaining mineralocorticoid, midodrine, a selective
peripherally acting α-adrenergic agent, and droxidopa, an
orally active synthetic precursor of norepinephrine [41].
Pyridostigmine has been found to be eﬀective in neurogenic
orthostatic hypotension but has not been formally tested
in PD [42]. Reduction in dopaminergic medication may
be warranted if these medications are not tolerated or if
orthostatic hypotension is severe.
Nonpharmacologic treatments for constipation include
regular exercise, adequate water intake, and diet including
symbiotic yogurts containing Biﬁdobacterium, fructoligosac-
charide, and bulking agents (ﬁbers, psyllium, and polycar-
bophil). A dietary herb extract, Dai-kenchu-to, has been
found to ameliorate PD-related constipation [43]. Osmotic
laxatives including magnesium sulfate and polyethylene
glycol can be eﬀective. Other laxatives include lubipros-
tone [44] and macrogol [45]. Serotonergic agents such as
cisapride [46], mosapride citrate [47], tegaserod [48], and
pyridostigmine [49], an acetylcholinesterase inhibitor, have
been shown to be beneﬁcial as well. Constipation in PD
may be associated with focal dystonia of the puborectalis
muscle,and botulinum toxin Ainjections tothe puborectalis
muscle have demonstrated clinical beneﬁt [50]. Sacral nerve
stimulation has shown some promise [51]; however, it
has not been extensively studied and is not widely used.
Reduction of dopaminergic medications, amantadine, and
anticholinergics should also be considered. Highlighting the
complexity of the pathophysiology involved in PD-related
constipation, some dopaminergic agents such as apomor-
phine [52] and intrajejunal continuous infusion of levodopa
[53] can improve constipation and bowel dysfunction.
3.Sleep
Sleep dysfunction is very common in PD, seen in 60–
98% of patients [54], and if severe enough can lead to
decreased quality of life, impaired function, and caregiver
burden. Many sleep problems, are intrinsic to PD, such as
fragmented sleep, nighttime sleep problems and daytime
sleepiness. Complicating matters, all of these symptoms can
be associated with dopaminergicmedications[55],and these
eﬀects are dose related [56]. Dopaminergic medication is
thought to have a desynchronizing eﬀect on sleep architec-
ture that causes disruption of sleep continuity [57]. Low-
dose dopamine agonists have been associated with insomnia,
whereas higherdosescan lead toexcessive daytime sleepiness
(EDS). EDS has been deﬁned as those patients who are
experiencing unusually severe sleepiness during the day,
sleeping more than 2 hours in the daytime, or falling asleep
t h r e eo rm o r et i m e sad a y[ 58]. “Sleep attacks,” sudden
transitions from wakefulness to sleep without a prodrome,
were ﬁrst described in patients treated with pramipexole
or ropinirole [59]. Sleep attacks may be a severe form of
excessive daytime sleepiness, and the prevalence in patients
treated with dopaminergic medications has been reported
to be as high as 43% [60]. While initially associated with
dopamine agonists, they can be induced by levodopa as
well. One study showed that levodopa monotherapy carries
the lowest risk, and combination therapy with levodopa
and dopamine agonists has the highest risk [61] of sleep
attacks. Drugs that are not associated with excessive daytime
sleepiness/sleep attacks include selegiline, amantadine, and
entacapone. Selegiline and amantadine have stimulating
properties and therefore can induce problems with sleep
initiation. Sleep attacks are important to be aware of
because these abrupt sleep episodes can have dangerous
implications, particularly when driving; thus, it is important
to continuously monitor for this side eﬀect.
Management of these sleep issues ﬁrst begins with edu-
cation regarding healthy sleep hygiene. Patients should try
to maintain regular sleep/wake schedules, exercise regularly,
and minimize the use of alcohol and caﬀeine. Some PD
patients have coexisting sleep disorders, including sleep
apnea and restless legs syndrome (RLS), and in these cases,
a referral to a sleep specialist may be necessary. Physicians
should carefully review medication lists and remove those
that may be contributing to sleepiness. Medications that may
be stimulating should be given earlier in the day. Dopamin-
ergic medication may need to be reduced or discontinued,
particularly in cases involving sleep attacks. The use of
prolonged release dopamine agonists should be considered,
as a recent study using ropinirole prolonged release demon-
strated improvedsubjectivequalityofsleep,reduceddaytime
sleepiness, and disappearance of sleep attacks in some PD
patients [62]. Possible pharmacologic therapies for daytime
sleepiness that have demonstrated beneﬁt in PD patients
include methylphenidate [63], modaﬁnil [64], and sodium4 Parkinson’s Disease















oxybate [65]. For fragmented sleep and sleep initiation,
melatonin, a neurohormone produced in the pineal gland at
night, has been shown to improve sleep quality and daytime
sleepiness [66]. Patients who have undergone deep brain
stimulation (DBS) of the subthalamic nucleus (STN) have
reported improvements in nocturnal sleep [67]; however, it
is not clear how DBS aﬀects daytime sleepiness.
4.Conclusion
The management of dopamine-induced nonmotor symp-
tomsofPDcanbechallenging, especially astreatment strate-
gies often involve tapering oﬀ of these drugs, and such
changes to therapy can worsen motor symptoms (Table 1).
However, these eﬀects of dopaminergic therapy are impor-
tant to recognize given the impact they can have on
patients’ quality of life. Hallucinations and psychosis can be
frightening to both patients and their loved ones. ICD and
DDS can lead to serious personal, social, and ﬁnancial con-
sequences, and autonomic and sleep symptoms can often
be more debilitating than PD motor symptoms themselves.
Thus, it is important to exercise sound clinical judgment
when initiating and titrating medication and closelymonitor
patients with the involvement of family and caregivers.
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